

R&D Pipelines Covering a Wide Variety of Therapeutic Areas

(update as of Mar. 30, 2023)



Pre-Clinical		Phase 1		Phase 2	Phase 3	Approved
JS011 Undisclosed	JS013 CD93	JS006 TIGIT	JS007 CTLA-4	Tifcemalimab BTLA	Senaparib PARP	Toripalimab PD-1
JS018 IL-2	JS104 Pan-CDK	JS009 CD112R	JS014 IL-21	JS005 IL-17A	Bevacizumab VEGF	Adalimumab TNF- α
JS114 Nectin4 ADC	JS115 BCMA ADC	JS015 DKK1	JS105 PI3K- α		Ongericimab PCSK9	Deuremidevir Hydrobromide RdRp
JS120 IDH1	JS121 SHP2	JS107 Claudin18.2 ADC	JS111 EGFR exon 20			Etesevimab* S protein
JS122 FGFR2	JS123 ATR	JS112 Aurora A	JS113 EGFR 4th Gen			
JS205 EGFR \times cMet	JS206 IL-2 \times PD-1	JS001sc PD-1	JS110 XPO1			
JS207 PD-1 \times VEGF	JS208 Undisclosed	JS203 CD3 \times CD20	JS019 CD39			
JS209 CD112R \times TIGIT	JS211 PD-L1 \times Undisclosed	JS003 PD-L1	JS012 Claudin 18.2			
JS401 ANGPTL3	VV993 3CLpro	JS101 Pan-CDK	JS108 Trop2 ADC			
JS008 Undisclosed	JT109 Vaccine	JS116 KRAS	JS201 PD-1 \times TGF- β			
		JS010 CGRP	JS103 Uricase			
		UBP1213sc BLYS	JS026 S protein			

- Oncology
- Metabolism
- Immunology
- Neuroscience
- Infectious Disease

*Received FDA Emergency Use Authorization in 2021